ALZN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders...

Stats
Today's Volume	13 819.00
Average Volume	55 835.00
Market Cap	4.94M
EPS	$0 ( 2024-03-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.400
ATR14	$0.0140 (1.95%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Ault Milton C Iii	Buy	1 000	Common Stock
2024-04-01	Ault Milton C Iii	Buy	334	Common Stock
2024-01-05	Ault Milton C Iii	Buy	2 000	Common Stock
2024-03-26	Ault Milton C Iii	Buy	780 000	Warrants
2024-03-26	Ault Milton C Iii	Buy	780	Series B Convertible Preferred Stock

INSIDER POWER
-7.90
Last 96 transactions
Buy: 11 786 230 \| Sell: 5 921 131

Alzamend Neuro, Inc. Correlation

10 Most Positive Correlations
SEDG	0.983
IMUX	0.974
CFRX	0.973
RIDE	0.973
BXRX	0.971
ELEV	0.97
BNGO	0.969
IRDM	0.968
FNCH	0.967
RELI	0.967

10 Most Negative Correlations
ADAL	-0.973
SLMBP	-0.973
HCNE	-0.971
VMGA	-0.97
JUGG	-0.967
IXAQ	-0.966
HORI	-0.966
GPAC	-0.966
LCAA	-0.964
IBEX	-0.962

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alzamend Neuro, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-23 066.00 (0.00 %)
EPS:	$-2.29

FY	2023
Revenue:	$0
Gross Profit:	$-23 066.00 (0.00 %)
EPS:	$-2.29

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.09

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0594

Financial Reports:

No articles found.

Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.